Market Cap 219.22M
Revenue (ttm) 55.25M
Net Income (ttm) -334.33M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -605.12%
Debt to Equity Ratio -0.60
Volume 12,637,899
Avg Vol 1,741,678
Day's Range N/A - N/A
Shares Out 69.81M
Stochastic %K 42%
Beta 0.15
Analysts Strong Sell
Price Target $18.50

Latest News on PHAT

Frazier Life Sciences Appoints Aditya Kohli to Partner

Apr 17, 2025, 8:00 AM EDT - 24 days ago

Frazier Life Sciences Appoints Aditya Kohli to Partner

HLVX


Phathom Pharmaceuticals Announces Leadership Succession

Apr 1, 2025, 8:00 AM EDT - 5 weeks ago

Phathom Pharmaceuticals Announces Leadership Succession


Phathom Pharma Is A Buy Before July PDUFA

Jan 1, 2024, 6:41 AM EST - 1 year ago

Phathom Pharma Is A Buy Before July PDUFA


Following Up On Phathom Pharmaceuticals

Oct 5, 2023, 12:43 PM EDT - 1 year ago

Following Up On Phathom Pharmaceuticals


Phathom Pharmaceuticals Reports Second Quarter 2023 Results

Aug 10, 2023, 8:01 AM EDT - 1 year ago

Phathom Pharmaceuticals Reports Second Quarter 2023 Results


Phathom Pharma: Time To Take Profits (Rating Downgrade)

Jul 14, 2023, 4:12 PM EDT - 1 year ago

Phathom Pharma: Time To Take Profits (Rating Downgrade)